AIMS: To determine if bilateral S3 lead placement during the stage I trial period improves the "success" rate for advancing to stage II (permanent) sacral neuromodulator placement. METHODS: A retrospective chart review of 124 (20 male and 104 female) patients undergoing stage I sacral neuromodulation (InterStim, Medtronic, Minneapolis, Minnesota) implantation for the treatment of refractory voiding dysfunction was performed. Patients were divided into two cohorts based on unilateral versus bilateral stage I lead placement in the S3 foramina. Both groups were then evaluated and compared with regards to overall "success", defined as progression from stage I to stage II placement. RESULTS: Fifty-five (44%) patients underwent unilateral stage I lead placement and 69 (56%) received bilateral S3 leads. Successful stage I trials were reported in 32/55 (58%) and 53/69 (76%) of unilateral and bilateral cohorts, respectively (P = 0.03). Five wound infections were reported-2 (3.6%) following unilateral and 3 (4.3%) after bilateral stage I lead placement. No other complications were encountered. CONCLUSIONS: Bilateral stage I neuromodulation trial provides a significantly higher rate of improvement in refractory voiding symptoms to allow for the progress to stage II implantation. (c) 2008 Wiley-Liss, Inc.
AIMS: To determine if bilateral S3 lead placement during the stage I trial period improves the "success" rate for advancing to stage II (permanent) sacral neuromodulator placement. METHODS: A retrospective chart review of 124 (20 male and 104 female) patients undergoing stage I sacral neuromodulation (InterStim, Medtronic, Minneapolis, Minnesota) implantation for the treatment of refractory voiding dysfunction was performed. Patients were divided into two cohorts based on unilateral versus bilateral stage I lead placement in the S3 foramina. Both groups were then evaluated and compared with regards to overall "success", defined as progression from stage I to stage II placement. RESULTS: Fifty-five (44%) patients underwent unilateral stage I lead placement and 69 (56%) received bilateral S3 leads. Successful stage I trials were reported in 32/55 (58%) and 53/69 (76%) of unilateral and bilateral cohorts, respectively (P = 0.03). Five wound infections were reported-2 (3.6%) following unilateral and 3 (4.3%) after bilateral stage I lead placement. No other complications were encountered. CONCLUSIONS: Bilateral stage I neuromodulation trial provides a significantly higher rate of improvement in refractory voiding symptoms to allow for the progress to stage II implantation. (c) 2008 Wiley-Liss, Inc.
Authors: A Zegrea; J Kirss; T Pinta; T Rautio; P Varpe; M Kairaluoma; M Aho; C Böckelman; M Lavonius Journal: Tech Coloproctol Date: 2020-01-21 Impact factor: 3.781
Authors: Dick Aw Janssen; Frank Mj Martens; Liesbeth L de Wall; Hendrikje Mk van Breda; John Pfa Heesakkers Journal: Med Devices (Auckl) Date: 2017-06-01
Authors: Katherine Shapiro; Natalie Pace; Tara Morgan; Haotian Cai; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai Journal: Front Neurosci Date: 2020-02-07 Impact factor: 4.677